Individual generic drug information
Extracted information for Domperidone only.
Relief of nausea and vomiting ▶BY MOUTH ▶Child 12–17 years (body-weight 35 kg and above): 10 mg up to 3 times a day for a usual maximum of 1 week; maximum 30 mg per day ▶Adult (body-weight 35 kg and above): 10 mg up to 3 times a day for a usual maximum of 1 week; maximum 30 mg per day Gastro-intestinal pain in palliative care ▶BY MOUTH ▶Adult: 10 mg 3 times a day, before meals
Source page 473
Cardiac disease. conditions where Nervous system cardiac conduction is, or could be, impaired. gastro- intestinal haemorrhage. gastro-intestinal mechanical obstruction. gastro-intestinal mechanical perforation. if increased gastro-intestinal motility harmful. prolactinoma
Source page 473
Patients over 60 years—increased risk of ventricular arrhythmia (in adults)
Source page 473
Palliative care For further information on the use of domperidone in palliative care, see www.medicinescomplete. com/#/content/palliative/domperidone.
Source page 473
Extracted information for Domperidone only.
MHRA/CHM ADVICE (UPDATED DECEMBER 2019): DOMPERIDONE FOR NAUSEA AND VOMITING: LACK OF EFFICACY IN CHILDREN; REMINDER OF CONTRA-INDICATIONS IN ADULTS AND ADOLESCENTS Domperidone is no longer indicated for the relief of nausea and vomiting in children aged under 12 years or those weighing less than 35 kg. A European review concluded that domperidone is not as effective in this population as previously thought and alternative treatments should be considered. Healthcare professionals are advised to adhere to the licensed dose and to use the lowest effective dose for the shortest possible duration (max. treatment duration should not usually exceed 1 week). Healthcare professionals are also reminded of the existing contra-indications for use of domperidone (see Contra-indications, Hepatic impairment, and Interactions).
Source page 473
→Appendix 1: domperidone
Source page 473
▶Common or very common Dry mouth ▶Uncommon Anxiety. asthenia. breast abnormalities. diarrhoea. drowsiness. headache. lactation disorders. libido loss ▶Frequency not known Arrhythmias. depression. gynaecomastia. menstrual cycle irregularities. movement disorders. oculogyric crisis. QT interval prolongation. seizure. sudden cardiac death. urinary retention
Source page 473
Use only if potential benefit outweighs risk.
Source page 473
Amount too small to be harmful.
Source page 473
Manufacturer advises avoid in moderate to severe impairment.
Source page 473
Dose adjustments Reduce frequency.
Source page 473
Extracted information for Domperidone only.
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Oral suspension CAUTIONARY AND ADVISORY LABELS 22 ▶Domperidone (Non-proprietary) Domperidone 1 mg per 1 ml Domperidone 1mg/ml oral suspension sugar-free | 200 ml P £24.85 DT = £24.85 Tablet CAUTIONARY AND ADVISORY LABELS 22 ▶Domperidone (Non-proprietary) Domperidone (as Domperidone maleate) 10 mg Domperidone 10mg tablets | 30 tablet P £2.71 DT = £0.89 | 100 tablet P £9.04 DT = £2.97 ▶Motilium (Zentiva) Domperidone (as Domperidone maleate) 10 mg Motilium 10mg tablets | 30 tablet P £2.71 DT = £0.89 | 100 tablet P £9.04 DT = £2.97
Source page 473
Extracted information for Domperidone only.
Arrhythmia Patients and their carers should be told how to recognise signs of arrhythmia and advised to seek medical attention if symptoms such as palpitation or syncope develop. Medicines for Children leaflet: Domperidone for gastro- oesophageal reflux www.medicinesforchildren.org.uk/ domperidone-gastro-oesophageal-reflux
Source page 473
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
10 mg up to 3 times
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 473
First line only; read the complete Indications and dose section above.
10 mg 3 times a day, before meals
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 473
